This inventor holds 1 USPTO granted patent. Top assignee: Other. Active years: 2015.
Company Filing History:
1 out of 834,307 Years Active: 2015
Title: Gillian Murphy: Innovator in Antibody Therapeutics
Introduction
Gillian Murphy is a prominent inventor based in Cambridge, GB. She has made significant contributions to the field of antibody therapeutics, particularly in the development of anti-TACE antibody molecules. Her work focuses on innovative approaches to cancer treatment through targeted therapies.
Latest Patents
Gillian Murphy holds a patent for "Anti-tace antibody molecules and their uses." This patent discloses anti-TACE (ADAM17) antibodies that are capable of binding to TACE, acting as antagonists of its biological activities. The antibodies are designed to bind in a cross-domain manner, involving residues from both the catalytic domain and the cysteine-rich/disintegrin domains. This unique binding mechanism enhances the specificity of the antibody and improves the inhibition of TACE's biological activity. The therapeutic applications of these antibodies are particularly relevant for cancer treatment.
Career Highlights
Throughout her career, Gillian has demonstrated a commitment to advancing medical science through her innovative research. Her work has the potential to significantly impact cancer therapies, providing new avenues for treatment options.
Collaborations
Gillian has collaborated with notable colleagues, including John Gerald McCafferty and Christopher Tape. These partnerships have contributed to the development and refinement of her groundbreaking research.
Conclusion
Gillian Murphy is a trailblazer in the field of antibody therapeutics, with her patent on anti-TACE antibodies representing a significant advancement in cancer treatment. Her innovative work continues to inspire and pave the way for future research in this vital area of medicine.